NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks increased 3.9%, with the Danish rising 13.1%. Saniona rose 146% following a massive partnership deal with Acadia for SAN711 at a total of MUSD 28 upfront, MUSD 610 in milestone payments, and up to low double-digit royalties on sales. SynAct Pharma received EU approval for their phase 2b study, and Curasight has its last day of trading tomorrow for their TO2 warrants.
15 of the 22 Danish biotech companies had a positive share price development in the past week and 13 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. 4 Danish healthcare stocks with +100% YTD return.
Danish company news
No news in the past week
No news in the past week
Biosergen Doses First Patients in Second Cohort of BSG005 Clinical Trial for Life-Threatening Fungal Infections (Link)
No news in the past week
CS MEDICA: Q4 Interim report, July – September 2024 (Link)
The last day of trading in warrants of series TO2 is on the 3rd of December 2024, and exercise period ends on the 5th of December 2024 (Link)
SEB maintains a valuation range midpoint at DKK 54 per share (Link)
Agreement Reached on Permanent Medicinal Cannabis Scheme in Denmark (Link)
No news in the past week
No news in the past week
FluoGuide A/S publishes interim report for the period January – September 2024 (Link)
Svenska Handelsbanken cut its price target from DKK 2,250 to DKK 2,000.
No news the past week
Q3 2024 REPORT (Link)
No news the past week
No news the past week
Saniona publishes its interim report for the third quarter of 2024 (Link)
Saniona Announces Licensing Agreement with Acadia Pharmaceuticals for SAN711 in Neurological Diseases (Link)
No news the past week
SynAct Pharma receives EU trial approval for the Phase 2b ADVANCE study with resomelagon (AP1189) (Link)
No news the past week
No news the past week
Y-mAbs to Participate at Citi’s 2024 Global Healthcare Conference (Link)
No news the past week
Share price development – Danish stocks
On average, Danish biotech and healthcare stocks delivered a positive return of 13.1% last week and 10.6% in the week prior to last week. Two very strong weeks were driven by a few stocks with stellar performances. Saniona rose 146% following a large partnership with Acadia Pharmaceuticals for SAN711. Saniona will receive up to MUSD 610 in milestone payments and MUSD 28 upfront as well as mid-single to low double digits on global net sales. Acadia also provides financial support for the ongoing phase 1 study and preparation for the phase 2 study. Further, SynAct Pharma received EU approval for the phase IIb trial with resomelagon (AP1189). Finally, Curasight is having its last day of trading in the warrants of series TO2 tomorrow, and SEB maintained its valuation of DKK 54 per share versus the exercise price of DKK 11.50 and current trading price around DKK 11.2.
Gubra continues to be the best-performing stock year-to-date with a return of 452%. Pila Pharma, Saniona and ViroGates have also generated more than a 100% return.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
In the past week, the all-Nordic Kapital Partner Nordic Healthcare Index (KPHC) increased 3.9% to 64,44 creating a small comeback after a poor start to November. The healthcare index performed strongly from the beginning of October last year until July and August of this year. However, since August, the index has declined rapidly alongside the other indexes in the Nordics, and the 1-year return for the KPHC index has almost been erased by the past months of poor performance.
The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year
The top three best-performing stocks in the past week
Saniona (146%) is a biotechnology company currently engaged in the research and development of drugs for the treatment of neurological and other autoimmune diseases. The drug portfolio is broad and includes drugs that are currently in various clinical phases. Some of the work is also carried out in collaboration with other players in the pharmaceutical industry. The stock increased after a partnership deal with Acadia Pharmaceuticals for SAN711 in neurological diseases, where Saniona will receive up to MUSD 610 in milestone payments and MUSD 28 upfront as well as mid-single to low double digits on global net sales. Acadia also provides financial support for the ongoing phase 1 study and preparation for the phase 2 study.
Nanexa (147%) is a drug delivery company with a proprietary platform used for the formulation of injectable depot drugs that create a delivery of drugs into the bloodstream. The PharmaShell process is based on ALD (Atomic Layer Deposition) technology that encapsulates drug particles with a thin shell and creates the opportunity for pharmaceutical companies to develop new products. Nanexa has collaborations with several pharmaceutical companies, mainly around the Nordic market.
Immunovia (76%) is a biotechnology company. The company’s research and development is focused on molecular diagnostics, where the business focuses on driving development and change in current working methods for diagnosing complex cancers and immune diseases. The vision is to establish blood-based tests for the early identification of different types of pancreatic cancer.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
